Steven Mindrup, MD
Urology · Cedar Rapids, IANPI 1447298005
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2019 at $4,237 and has fallen 95.9% since, to $174 in 2025.
Across 175 payments — averaging $47.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Intuitive Surgical$1K
- Valencia Technologies Corporation$1K
- Neotract Inc.$1K
- 180 Medical, Inc.$552
- Astellas Pharma US Inc$318
- plus $2K from 28 others
What the payments were for
- Travel & lodging$3,95548%
- Food & beverage$4,07649%
- Education$2693%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 12 | $1,687 |
| Intuitive Surgical | 9 | $1,248 |
| Valencia Technologies Corporation | 6 | $1,240 |
| Neotract Inc. | 15 | $1,199 |
| 180 Medical, Inc. | 26 | $552 |
| Astellas Pharma US Inc | 7 | $318 |
| Teleflex LLC | 6 | $283 |
| Boston Scientific | 4 | $215 |
| Pfizer | 23 | $206 |
| AbbVie(2 entities) | 10 | $205 |
| Dendreon Pharmaceuticals LLC | 7 | $168 |
| Bayer | 7 | $114 |
| Axonics, Inc. | 5 | $103 |
| Palette Life Sciences, Inc. | 1 | $77 |
| Merck | 4 | $75 |
| Johnson & Johnson | 4 | $72 |
| Urogen Pharma, Inc. | 3 | $70 |
| Coloplast | 5 | $70 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $37 |
| Verity Pharmaceuticals Inc. | 2 | $36 |
| Myovant Sciences Inc. | 2 | $32 |
| Novartis | 1 | $32 |
| Rochester Medical Corporation | 1 | $29 |
| Cook Medical LLC | 2 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Civco Medical Instruments | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Endo USA, Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Telix Pharmaceuticals | 1 | $14 |
| Vertex | 1 | $14 |
| Olympus America Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,353
- Da Vinci Surgical System$1,091
- eCoin Device Kit$1,052
- UroLift$846
How this compares
$8,301 in reported general payments places this provider in the 80th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $296,304 |
| MyrbetriqMirabegron | 167 | $111,354 |
| OrgovyxRelugolix | 12 | $31,982 |
| GemtesaVibegron | 22 | $17,209 |
| NitrofurantoinNitrofurantoin Macrocrystal | 257 | $9,443 |
| Tamsulosin Hcl | 765 | $7,098 |
| VesicareSolifenacin Succinate | 12 | $6,915 |
| Solifenacin Succinate | 173 | $5,962 |
| PremarinEstrogens, Conjugated | 14 | $5,925 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 47 | $5,909 |
| Oxybutynin Chloride | 320 | $5,282 |
| Trimethoprim | 62 | $4,910 |
| Finasteride | 336 | $4,038 |
| Methenamine Hippurate | 65 | $2,829 |
| Tolterodine Tartrate | 35 | $2,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq, Vesicare | $318 | $414,573200 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $43 | $49,19034 claims |
| PfizerPremarin | $206 | $5,92514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 urology providers in Iowa.
Other urology in Cedar Rapids
- Jonathan RippentropCedar Rapids$15K
- Gregory JandaCedar Rapids$12K
- Michael MoriartyCedar Rapids$8K
- Matthew FerroniCedar Rapids$5K
- Thomas RichardsonCedar Rapids$5K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.